<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Agents interfering with the renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) were consistently shown to lower the incidence of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM), as compared to other <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi>, in hypertensive high-risk populations </plain></SENT>
<SENT sid="1" pm="."><plain>The mechanisms underlying this protective effect of <z:mp ids='MP_0011356'>RAS</z:mp> blockade using <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi> or angiotensin-receptor blockers on <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism are not fully understood </plain></SENT>
<SENT sid="2" pm="."><plain>In this article, we will review the evidence from randomized controlled trials and discuss the proposed mechanisms as to how <z:mp ids='MP_0011356'>RAS</z:mp> interference may delay the <z:hpo ids='HP_0003674'>onset</z:hpo> of T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>In particular, as T2DM is characterized by β-cell dysfunction and <z:hpo ids='HP_0001513'>obesity</z:hpo>-related <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, we address the mechanisms that underlie <z:mp ids='MP_0011356'>RAS</z:mp> blockade-induced improvement in β-cell function and insulin sensitivity </plain></SENT>
</text></document>